Are monoclonal antibodies effective in patients with severe obesity in SARS‐CoV‐2 infected?. Issue 2 (9th February 2023)

• Record Type: Journal Article
• Authors: Ucciferri, Claudio; Moffa, Livia; Moffa, Samanta; Vecchiet, Jacopo; Falasca, Katia
• Is Part Of: Immunity, inflammation and disease. Volume 11:Issue 2(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2023-02-09
• Subjects: COVID‐19 -- monoclonal antibody -- obesity; Immunology -- Periodicals; Immunity -- Periodicals; Inflammation -- Periodicals; 616.079
• DOI: 10.1002/iid3.771
• Languages: English
• ISSNs: 2050-4527

Abstract

Abstract: It is important to block SARS‐CoV‐2 infection immediately with early therapies, such as monoclonal antibodies (MonoAbs). Also, several studies show that obesity is associated with a high risk of severe COVID‐19 disease. We enrolled 32 SARS‐CoV‐2 infected patients who received MonoAbs, all patients were not vaccinated for SARS‐CoV‐2, and they received therapy after 7 ± 2 days from the onset of COVID‐19 symptoms. In the days following administration, patients followed home therapy with Pidotimod 800 mg bid for 10 days and cholecalciferol 2000 UI for 20 days, prescribed the same day they received MonoAbs therapy. Our study found that there are no differences in the therapeutic response between obese and nonobese patients with SARS‐CoV‐2 infection undergoing MonoAbs therapy, in fact, none of them underwent hospitalization. Furthermore, the effect of the immunostimulant Pidotimod and cholecalciferol may have contributed to the resolution of COVID‐19 symptoms in these patients. Abstract : There are no differences in the therapeutic response between obese and nonobese patients with SARS‐CoV‐2 infection undergoing MonoAbs therapy The effect of the immunostimulant Pidotimod and cholecalciferol may contribute to the resolution of COVID‐19 symptoms in patients with SARS‐CoV‐2 infection. Early therapies in COVID‐19, such as monoclonal antibodies, reduce the risk of progression to severe disease.